In a cohort of anti-PD-1 treated melanoma patients, TRIM28 was significantly less expressed in responders compared to non-responders, while loss of SEATB1 increased infiltration of effector CD8+T cells into the tumor microenvironment, a prerequisite for response to ICB [129]. The gene discussed is CD8A; the disease is neoplasm.